Results from Investigational IMPROVE-IT Study of VYTORIN® (ezetimibe and simvastatin) Published in the New England Journal of Medicine

Dateline City:

KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK),
known as MSD outside the United States and Canada, today announced that
the New England Journal of Medicine published the results
of the IMPROVE-IT trial, an investigational study comparing treatment
with VYTORIN® (ezetimibe and simvastatin) to treatment with
simvastatin alone in more than 18,000 patients presenting with acute
coronary syndromes.

Language:

English

Contact:

MerckMedia:Pamela Eisele, [phone]Tracy Ogden, [phone]orInvestor:Justin Holko, [phone]

Ticker Slug:

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Product News - June 3, 2015 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news